Insiders Advisor
  • Stocks
  • World News
  • Business
  • Politics
  • Stocks
  • World News
  • Business
  • Politics

Insiders Advisor

Business

Hims & Hers Health says it will offer compounded GLP-1 injections

by May 22, 2024
May 22, 2024
Hims & Hers Health says it will offer compounded GLP-1 injections

Digital pharmacy startup Hims & Hers Health is introducing access to compounded GLP-1 weight loss injections, the company announced Monday.

Shares of the company surged.

The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December. But GLP-1 medications — such as Ozempic and Wegovy, which have skyrocketed in popularity — were not previously offered as part of that program.

Customers can access the compounded GLP-1 medications via a prescription from a licensed health-care provider on the Hims & Hers platform. Hims & Hers said it plans to make branded GLP-1 medications available to its customers once supply is consistently available.

The company’s oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month.

Even before it added compounded GLP-1s to its portfolio, Hims & Hers said in its fourth-quarter earnings report that it expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The company plans to offer updated guidance in its next earnings report.

The GLP-1 market, dominated so far by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as the drugs get expanded approval from health regulators and increased health coverage.

GLP-1s mimic a hormone produced in the gut to tamp down a person’s appetite and regulate their blood sugar. When those medications are in shortage, certain manufacturers can prepare a compounded version if they meet U.S. Food and Drug Administration requirements.

The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient’s needs.

In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available.

Hims & Hers CEO Andrew Dudum told CNBC that the company is “confident” that customers will be able to access a consistent supply of the compounded medications.

Dudum said Hims & Hers has spent the last year learning about the GLP-1 supply chain and has partnered with one of the largest generic manufacturers in the country that has FDA oversight.

“We have a certain degree of exclusivity with that facility that will guarantee our consumers consistent volume and supply,” he said.

This post appeared first on NBC NEWS
previous post
Hims & Hers Health says it will offer compounded GLP-1 injections
next post
Trump Media lost $327.6 million in the first quarter of the year on revenue of just $770,500

Related Posts

‘Absurd’: NTSB chair blasts Boeing for failing to...

March 8, 2024

Stock market has worst day since 2022 as...

July 25, 2024

Kia recalling 427,000 Telluride SUVs because they might...

March 30, 2024

Trader Joe’s recalls 653,000 scented candles due to...

August 16, 2024

Chase customers sue over fees for depositing checks...

February 22, 2024

Willow Bay and Bob Iger to take controlling...

July 18, 2024

Home prices hit record high in June on...

August 28, 2024

Apple sues former Vision Pro employee for allegedly...

July 2, 2025

Hasbro forecasts as much as $300 million impact...

April 25, 2025

23andMe to delist from Nasdaq, deregister with SEC

May 28, 2025

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Latest News

    • Tariff case pits Cato Institute against Trump over ‘unlimited’ executive power under emergency law

      July 9, 2025
    • Biden’s strange use of teleprompter in donor’s home infuriated supporters, dashed expectations

      July 9, 2025
    • Supreme Court lets Trump’s ‘wrecking ball’ federal job cuts proceed while legal fight continues

      July 8, 2025
    • Waymo offers teen accounts for driverless rides

      July 8, 2025
    • TikToker knocks Harris’ ‘weird’ take on never released interview: ‘Not good’

      July 8, 2025
    • ‘Who wouldn’t want it?’: Netanyahu open to receiving stealth bombers, bunker-busters from US

      July 8, 2025

    Categories

    • Business (1,297)
    • Politics (6,314)
    • Stocks (904)
    • World News (460)
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: insidersadvisor.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 insidersadvisor.com | All Rights Reserved